Fibromyalgia syndrome: Mechanisms of abnormal pain processing

Primary Psychiatry

Volumn 13, Issue 9, 2006, Pages 66-71

  Staud, Roland ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFFECT; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; FIBROMYALGIA; HUMAN; IRRITABLE COLON; LOW BACK PAIN; MIGRAINE; NOCICEPTION; PAIN; PATHOGENESIS; REVIEW; SENSITIZATION; SLEEP; SYNDROME DELINEATION; TEMPOROMANDIBULAR JOINT DISORDER;

EID: 33748935993     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160-172.
2. Wolfe F. The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis. 1997;56(4):268-271.
3. Hadler NM. Is fibromyalgia a useful diagnostic label? Cleve Clin J Med. 1996;63(2):85-87.
4. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37(11):1593-1601.
5. Bradley LA, Alarcon GS, Sotolongo A, et al. Cerebrospinal fluid (CSF) levels of substance P (SP) are abnormal in patients with fibromyalgia (FM) regardless of traumatic or insidious pain onset [abstract]. Arthritis Rheum. 1998;41(suppl 9):S256.
6. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain. 1988;32(1):21-26.
7. Neeck G. Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients. Scand J Rheumatol Suppl. 2000;113:8-12.
8. Lautenschlager J, Bruckle W, Schnorrenberger CC, Muller W. Measuring pressure pain of tendons and muscles in healthy probands and patients with generalized tendomyopathy (fibromyalgia syndrome) [German]. Z Rheumatol. 1988;47(6):397-404.
9. Quimby LG, Block SR, Gratwick GM. Fibromyalgia: generalized pain intolerance and manifold symptom reporting. J Rheumatol. 1988;15(8):1264-1270.
10. Tunks E, Crook J, Norman G, Kalaher S. Tender points in fibromyalgia. Pain. 1988;34(1):11-19.
11. Mikkelsson M, Latikka P, Kautiainen H, Isomeri R, Isomaki H. Muscle and bone pressure pain threshold and pain tolerance in fibromyalgia patients and controls. Arch Phys Med Rehabil. 1992;73(9):814-818.
12. Kosek E, Ekholm J, Hansson P. Increased pressure pain sensibility in fibromyalgia patients is located deep to the skin but not restricted to muscle tissue. Pain. 1995;63(3):335-339.
13. Erratum in: Pain. 1996;64(3):605.
14. Loeser JD. What is chronic pain? Theor Med. 1991;12(3):213-225.
15. Price DD. Psychological Mechanisms of Pain and Analgesia: Progress in Pain Research and Management, Vol. 15. Seattle, WA: IASP Press; 1999.
16. Rainville P, Bao QV, Chretien P. Pain-related emotions modulate experimental pain perception and autonomic responses. Pain. 2005;118(3):306-318.
17. Merskey H, Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd ed. Seattle, WA: IASP Press; 1994.
18. Crofford LJ, Young EA, Engleberg NC, et al. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun. 2004;18(4):314-325.
19. Crofford LJ. The hypothalamic-pituitary-adrenal axis in fibromyalgia: Where are we in 2001? J Musculoskel Pain. 2002;10:215-220.
20. Bradley LA, Sotolongo A, Alberts KR, et al. Abnormal regional cerebral blood flow in the caudate nucleus among fibromyalgia patients and non-patients is associated with insidious symptom onset. J Musculoskel Pain. 1999;7(1-2):285-292.
21. Larson AA, Giovengo SL, Russell IJ, Michalek JE. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain. 2000;87(2):201-211.
22. Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol. 1999;26(7):1564-1569.
23. Simms RW. Fibromyalgia is not a muscle disorder. Am J Med Sci. 1998;315(6):346-350.
24. Sprott H, Bradley LA, Oh SJ, et al. Immunohistochemical and molecular studies of serotonin, substance P, galanin, pituitary adenylyl cyclase-activating polypeptide, and secretoneurin in fibromyalgic muscle tissue. Arthritis Rheum. 1998;41(9):1689-1694.
25. Sprott H, Salemi S, Gay RE, et al. Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres. Ann Rheum Dis. 2004;63(3):245-251.
26. Salemi S, Rethage J, Wollina U, et al. Detection of interleukin 1 beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol. 2003;30(1):146-150.
27. McIver KL, Evans C, Kraus RM, et al. NO-mediated alterations in skeletal muscle nutritive blood flow and lactate metabolism in fibromyalgia. Pain. 2006;120(1-2):161-169.
28. Graven-Nielsen T, Arendt-Nielsen L. Is there a relation between intramuscular hypoperfusion and chronic muscle pain. J Pain. 2002;3(4):261-263.
29. Elvin A, Siosteen AK, Nilsson A, Kosek E. Decreased muscle blood flow in fibromyalgia patients during standardised muscle exercise: a contrast media enhanced colour Doppler study. Eur J Pain. 2006;10(2):137-144.
30. Staud R, Vierck CJ, Robinson ME, Price DD. Overall fibromyalgia pain is predicted by ratings of local pain and pain related negative affect-possible role of peripheral tissues. Rheumatology (Oxford). In press.
31. Wigers SH. Fibromyalgia outcome: the predictive values of symptom duration, physical activity, disability pension, and critical life events-a 4.5 year prospective study. J Psychosom Res. 1996;41(3):235-243.
32. Macfarlane GJ, Thomas E, Papageorgiou AC, Scholium J, Croft PR, Silman AJ. The natural history of chronic pain in the community: a better prognosis than in the clinic? J Rheumatol. 1996;23(9):1617-1620.
33. Winfield JB. FMS as functional somatic syndrome. Arthritis Rheum. 2001;44:751-753.
34. Hunt IM, Silman AJ, Benjamin S, McBeth J, Macfarlane GJ. The prevalence and associated features of chronic widespread pain in the community using the 'Manchester' definition of chronic widespread pain. Rheumatology (Oxford). 1999;38(3):275-279.
35. Croft P, Rigby AS, Boswell R, Scholium J, Silman A. The prevalence of chronic widespread pain in the general population. J Rheumatol. 1993;20(4):710-713.
36. Benjamin S, Morris S, McBeth J, Macfarlane GJ, Silman AJ. The association between chronic widespread pain and mental disorder: a population-based study. Arthritis Rheum. 2000;43(3):561-567.
37. Forseth KO, Forre O, Gran JT. A 5.5 year prospective study of self-reported musculoskeletal pain and of fibromyalgia in a female population: Significance and natural history. Clin Rheumatol. 1999;18(2):114-121.
38. McBeth J, Macfarlane GJ, Benjamin S, Silman AJ. Features of somatization predict the onset of chronic widespread pairt results of a large population-based study. Arthritis Rheum. 2001;44(4):940-946.
39. Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50(3):944-952.
40. Thieme K, Turk DC, Flor H. Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med. 2004;66(6):837-844.
41. Raphael KG, Janal MN, Nayak S, Schwartz JE, Gallagher RM. Familial aggregation of depression in fibromyalgia: a community-based test of alternate hypotheses. Pain. 2004;110(1-2):449-460.
42. Woolf CJ. Windup and central sensitization are not equivalent. Pain. 1996;66(2-3):105-108.
43. Li J, Simone DA, Larson AA. Windup leads to characteristics of central sensitization. Pain. 1999;79(1):75-82.
44. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain. 2001;91(1-2):165-175.
45. Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology. 1987;26(8):1235-1238.
46. Mendell LM, Wall PD. Responses of single dorsal cord cells to peripheral cutaneous unmyelinated fibres. Nature. 1965;206:97-99.
47. Price DD, Mao J, Frenk H, Mayer DJ. The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man. Pain. 1994;59(2):165-174.
48. Staud R, Vierck CJ, Robinson ME, Price DD. Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal controls. J Pain. 2005:6(5):323-332.
49. Vierck CJ, Cannon RL, Fry G, Maixner W, Whitsel BL. Characteristics of temporal summation of second pain sensations elicited by brief contact of glabrous skin by a preheated thermode. J Neurophysiol. 1997;78(2):992-1002.
50. Woolf CJ, Costigan M. Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci U S A. 1999;96(14):7723-7730.
51. Staud R, Domingo M. Evidence for abnormal pain processing in fibromyalgia syndrome. Pain Med. 2001;2(3):208-215.
52. Staud R, Domingo M. New Insights into the pathogenesis of fibromyalgia syndrome. Med Aspects Hum Sex. 2001;1:51-57.
53. Vierck CJ, Staud R, Price DD, Cannon RL, Mauderli AP, Martin AD: The effect of maximal exercise on temporal summation of second pain (windup) in patients with fibromyalgia syndrome. J Pain. 2001;2(6):334-344.
54. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep. 2002;4(4):299-305.
55. Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain. 2002;99(1-2):49-59.
56. Staud R, Robinson ME, Vierck CJ Jr, Cannon RC, Mauderli AP, Price DD. Ratings of experimental pain and pain-related negative affect predict clinical pain in patients with fibromyalgia syndrome. Pain. 2003;105(1-2):215-222.
57. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24(8):450-455.
58. Wieseler-Frank J, Maier SF, Watkins LR. Glial activation and pathological pain. Neurochem Int. 2004;45(2-3):389-395.
59. Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines and pain enhancement. Neurosignals. 2005:14(4):166-174.
60. Watkins LR, Maier SF. When good pain turns bad. Current Directions in Psychological Science. 2003;12(6):232-236.
61. Salter MW. Cellular signalling pathways of spinal pain neuroplasticity as targets for analgesic development. Curr Top Med Chem. 2005;5(6):557-567.
62. Cook AJ, Woolf CJ, Wall PD, McMahon SB. Dynamic receptive field plasticity in rat spinal cord dorsal horn following C-primary afferent input. Nature. 1987;325(7000):151-153.
63. Henriksson KG. Is fibromyalgia a distinct clinical entity? Pain mechanisms in fibromyalgia syndrome. A myologist's view. Baillieres Best Pract Res Clin Rheumatol. 1999;13(3):455-461.
64. Bengtsson A, Henriksson KG, Larsson J. Muscle biopsy in primary fibromyalgia. Light-microscopical and histochemical findings. Scand J Rheumatol. 1986;15(1):1-6.
65. Bengtsson A, Henriksson KG, Jorteldt L, et al. Primary fibromyalgia. A clinical and laboratory study of 55 patients. Scand J Rheumatol. 1986;15(3):340-347.
66. Pongratz DE, Spath M. Morphologic aspects of fibromyalgia. Z Rheumatol. 1998;57(suppl 2):47-51.
67. Bennett RM, Clark SR, Goldberg L, et al. Aerobic fitness in patients with fibrositis. A controlled study of respiratory gas exchange and 133xenon clearance from exercising muscle. Arthritis Rheum. 1989;32(4):454-460.
68. Lund N, Bengtsson A, Thorborg P. Muscle tissue oxygen pressure in primary fibromyalgia. Scan J Rheumatol. 1986;15(2):165-173.
69. de Kerviler E, Leroy-Willig A, Jehenson P, Duboc D, Eymard B, Syrota A. Exercise-induced muscle modifications: study of healthy subjects and patients with metabolic myopathies with MR imaging and P-31 spectroscopy. Radiology. 1991;181(1):259-264.
70. Sluka KA, Kalra A, Moore SA. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve. 2001;24(1):37-46.
71. Park JH, Phothimat P, Oates CT, Hernanz-Schulman M, Olsen NJ. Use of P-31 magnetic resonance spectroscopy to detect metabolic abnormalities in muscles of patients with fibromyalgia. Arthritis Rheum. 1998;41(3):406-413.
72. Wall PD, Woolf CJ. Muscle but not cutaneous C-afferent input produces prolonged increases in the excitability of the flexion reflex in the rat. J Physiol. 1984;356:443-458.
73. Vierck CJ Jr. Mechanisms underlying development of spatially distributed chronic pain (fibromyalgia). Pain. In press.
74. Bazzichi L, Giannaccini G, Betti L, et al. Alteration of serotonin transporter density and activity in fibromyalgia. Arthritis Res Ther. 2006;8(4):R99.
75. Delgado PL. Serotonin noradrenaline reuptake inhibitors: new hope for the treatment of chronic pain. Int J Psychiatr Clin Pract. 2006;10:16-21.